[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586934":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":30,"locations":35,"responsibleParty":205,"collaborators":24,"id":207,"slug":24,"hasResults":208,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":24,"eligibilityCriteria":212,"healthyVolunteers":208,"sex":213,"minAge":214,"maxAge":24,"enrollmentInfo":215,"targetDuration":24,"studyType":218,"phases":219,"briefSummary":222,"conditions":223,"keywords":226,"overallStatus":38,"whyStopped":24,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":238},{"fullName":5,"class":6},"Bolt Biotherapeutics, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation","EXPERIMENTAL","Escalating doses followed by backfill of selected doses",[13],"Drug: BDC-4182",{"label":15,"type":10,"description":16,"interventionNames":17},"Dose Expansion","Expansion at determined RP2D",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","BDC-4182","Immune stimulating antibody conjugate (ISAC), consisting of an anti-claudin 18.2 monoclonal antibody conjugated to a TLR 7\u002F8 dual agonist",[9,15],null,[26],{"name":27,"affiliation":28,"role":29},"Bolt Clinical Development","Bolt Biotherapeutics","STUDY_DIRECTOR",[31],{"name":28,"role":32,"phone":33,"phoneExt":24,"email":34},"CONTACT","+1 650 434 8640","clinicaltrials@boltbio.com",[36,51,62,74,86,97,109,120,128,136,144,156,164,175,186,194],{"facility":37,"status":38,"city":39,"state":40,"zip":24,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"AUS Site 2","RECRUITING","Darlinghurst","New South Wales","Australia",{"type":43,"coordinates":44},"Point",[45,46],151.21925,-33.87939,{"lat":46,"lon":45},[49],{"name":50,"role":32,"phone":24,"phoneExt":24,"email":24},"Site 8002",{"facility":52,"status":38,"city":53,"state":40,"zip":24,"country":41,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"AUS Site 5","Westmead",{"type":43,"coordinates":55},[56,57],150.98768,-33.80383,{"lat":57,"lon":56},[60],{"name":61,"role":32,"phone":24,"phoneExt":24,"email":24},"Site 8005",{"facility":63,"status":38,"city":64,"state":65,"zip":24,"country":41,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"AUS Site 1","Birtinya","Queensland",{"type":43,"coordinates":67},[68,69],153.11913,-26.74322,{"lat":69,"lon":68},[72],{"name":73,"role":32,"phone":24,"phoneExt":24,"email":24},"Site 8001",{"facility":75,"status":38,"city":76,"state":77,"zip":24,"country":41,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"AUS Site 4","Clayton","Victoria",{"type":43,"coordinates":79},[80,81],145.11667,-37.91667,{"lat":81,"lon":80},[84],{"name":85,"role":32,"phone":24,"phoneExt":24,"email":24},"Site 8004",{"facility":87,"status":38,"city":88,"state":77,"zip":24,"country":41,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"AUS Site 3","Heidelberg",{"type":43,"coordinates":90},[91,92],145.06667,-37.75,{"lat":92,"lon":91},[95],{"name":96,"role":32,"phone":24,"phoneExt":24,"email":24},"Site 8003",{"facility":98,"status":38,"city":99,"state":24,"zip":24,"country":100,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"SK Site 2003","Seongnam-si","South Korea",{"type":43,"coordinates":102},[103,104],127.13778,37.43861,{"lat":104,"lon":103},[107],{"name":108,"role":32,"phone":24,"phoneExt":24,"email":24},"Site 2003",{"facility":110,"status":38,"city":111,"state":24,"zip":24,"country":100,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"SK Site 2001","Seoul",{"type":43,"coordinates":113},[114,115],126.9784,37.566,{"lat":115,"lon":114},[118],{"name":119,"role":32,"phone":24,"phoneExt":24,"email":24},"Site 2001",{"facility":121,"status":38,"city":111,"state":24,"zip":24,"country":100,"cosmosGeoPoint":122,"geoPoint":124,"contacts":125},"SK Site 2002",{"type":43,"coordinates":123},[114,115],{"lat":115,"lon":114},[126],{"name":127,"role":32,"phone":24,"phoneExt":24,"email":24},"Site 2002",{"facility":129,"status":38,"city":111,"state":24,"zip":24,"country":100,"cosmosGeoPoint":130,"geoPoint":132,"contacts":133},"SK Site 2004",{"type":43,"coordinates":131},[114,115],{"lat":115,"lon":114},[134],{"name":135,"role":32,"phone":24,"phoneExt":24,"email":24},"Site 2004",{"facility":137,"status":38,"city":111,"state":24,"zip":24,"country":100,"cosmosGeoPoint":138,"geoPoint":140,"contacts":141},"SK Site 2005",{"type":43,"coordinates":139},[114,115],{"lat":115,"lon":114},[142],{"name":143,"role":32,"phone":24,"phoneExt":24,"email":24},"Site 2005",{"facility":145,"status":38,"city":146,"state":24,"zip":24,"country":147,"cosmosGeoPoint":148,"geoPoint":152,"contacts":153},"TWN Site 9004","Kaohsiung City","Taiwan",{"type":43,"coordinates":149},[150,151],120.31333,22.61626,{"lat":151,"lon":150},[154],{"name":155,"role":32,"phone":24,"phoneExt":24,"email":24},"Site 9004",{"facility":157,"status":38,"city":146,"state":24,"zip":24,"country":147,"cosmosGeoPoint":158,"geoPoint":160,"contacts":161},"TWN Site 9005",{"type":43,"coordinates":159},[150,151],{"lat":151,"lon":150},[162],{"name":163,"role":32,"phone":24,"phoneExt":24,"email":24},"Site 9005",{"facility":165,"status":38,"city":166,"state":24,"zip":24,"country":147,"cosmosGeoPoint":167,"geoPoint":171,"contacts":172},"TWN Site 9001","Taichung",{"type":43,"coordinates":168},[169,170],120.6839,24.1469,{"lat":170,"lon":169},[173],{"name":174,"role":32,"phone":24,"phoneExt":24,"email":24},"Site 9001",{"facility":176,"status":38,"city":177,"state":24,"zip":24,"country":147,"cosmosGeoPoint":178,"geoPoint":182,"contacts":183},"TWN Site 9003","Taipei",{"type":43,"coordinates":179},[180,181],121.52639,25.05306,{"lat":181,"lon":180},[184],{"name":185,"role":32,"phone":24,"phoneExt":24,"email":24},"Site 9003",{"facility":187,"status":38,"city":177,"state":24,"zip":24,"country":147,"cosmosGeoPoint":188,"geoPoint":190,"contacts":191},"TWN Site 9006",{"type":43,"coordinates":189},[180,181],{"lat":181,"lon":180},[192],{"name":193,"role":32,"phone":24,"phoneExt":24,"email":24},"Site 9006",{"facility":195,"status":38,"city":196,"state":24,"zip":24,"country":147,"cosmosGeoPoint":197,"geoPoint":201,"contacts":202},"TWN Site 9002","Taoyuan",{"type":43,"coordinates":198},[199,200],121.29696,24.99368,{"lat":200,"lon":199},[203],{"name":204,"role":32,"phone":24,"phoneExt":24,"email":24},"Site 9002",{"type":206,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100586934",false,"NCT06921837","A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer","A Phase 1\u002F2, First-in-Human, Dose Escalation and Expansion Study of BDC-4182 as a Single Agent in Patients With Advanced Gastric and Gastroesophageal Cancer","Key Inclusion Criteria:\n\n* Has disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1.\n* Subjects must have histologically\u002Fcytologically confirmed gastric or gastroesophageal cancer that is metastatic (Stage 4) or unresectable (Stage 3).\n* Subjects must have received at least 1-2 prior lines of locally available standard therapies or must be intolerant of standard therapies.\n* For subjects in escalation: If prior Claudin 18 IHC expression is known, the subject must have some degree of Claudin 18 expression as defined as Positive or have expression ≥ 1% of tumor cells IHC ≥ 2+. Consult with Medical Monitor as needed.\n* Adequate organ function\n* Agree to have a biopsy prior to enrollment, at acceptable risk in the judgement of the Investigator. If a biopsy is not safely accessible or clinically feasible, an adequate archival tumor sample must be submitted.\n\nKey Exclusion Criteria:\n\n* Known central nervous system (CNS) metastases except for disease that is asymptomatic, clinically stable, and has not required steroids for at least 14 days before starting study treatment.\n* Cardiac disease, pulmonary disease, or hepatic disease\n* Active infection\n* History of inflammatory eye disease\n* Residual toxicity from a previous treatment\n* Any investigational agent or standard anti-cancer therapies within 28 days before starting study treatment or within 5 estimated elimination half-lives, whichever is shorter.","ALL","18 Years",{"count":216,"type":217},122,"ESTIMATED","INTERVENTIONAL",[220,221],"PHASE1","PHASE2","A first-in-human study using BDC-4182 as a single agent in gastric and gastroesophageal cancers",[224,225],"Gastric Cancer Adenocarcinoma Metastatic","Gastroesophageal Adenocarcinoma",[227,228],"Gastric Cancer","Gastroesophageal Cancer","2026-01-23",{"date":231,"type":232},"2026-01-27","ACTUAL",{"date":234,"type":232},"2025-05-26",{"date":236,"type":217},"2029-05",{"name":5,"class":6},16]